[Advances in the studies of refractory erectile dysfunction]

Area of Science:

• Urology
• Andrology
• Pharmacology

Context:

• Erectile dysfunction (ED) affects many individuals, with phosphodiesterase-5 inhibitors (PDE5I) as a primary treatment.
• PDE5I therapy is effective for approximately 80% of ED cases.
• Refractory ED, often associated with chronic conditions or post-prostatectomy, shows limited response to PDE5I alone.

Purpose:

• To review the complex signaling pathways involved in refractory ED.
• To explore alternative and combination therapies for ED cases unresponsive to PDE5I.

Summary:

• Refractory ED involves intricate signaling networks beyond the NO-cGMP pathway, including RhoA/Rho kinase and H2S.
• Understanding these complex pathways is crucial for developing effective treatments for PDE5I-resistant ED.
• Novel therapeutic strategies combining or alternative to PDE5I are being investigated to enhance treatment efficacy.

Impact:

• Advances in understanding refractory ED pathogenesis can lead to improved therapeutic outcomes.
• This review highlights the need for personalized treatment approaches for ED.
• Potential for new drug development targeting specific signaling pathways in refractory ED.